Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Therapy in Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Decompensated Cirrhosis of liver irrespective of etiology~Exclusion Criteria:~* Acute on chronic liver failure (fulfilling either APASL or CANONIC criteria of ACLF)~* Splenic diameter of more than 18 cm~* Concomitant HCC or other active malignancy~* Upper gastrointestinal bleeding in the previous 7 days~* Portal vein thrombosis~* Severe renal dysfunction as defined by creatnine \> 1.5mg/dl~* Severe cardiac dysfunction~* Uncontrolled diabetes (Hb A 1c ≥ 9) or diabetic retinopathy~* Acute infection or disseminate intravascular coagulation~* Active alcohol abuse in last 3 months~* Known hypersensitivity to GH~* HIV co-infection~* Pregnancy~* Refusal to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard Medical Therapy (Type: ACTIVE_COMPARATOR): Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
- Growth hormone (Type: ACTIVE_COMPARATOR): Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).